Three antiviral drugs have been used most widely against COVID-19: nirmatrelvir/ritonavir (sold as Paxlovid), molnupiravir, and remdesivir. Each works by a different mechanism to stop the virus from copying itself, and each carries its own set of trade-offs in terms of who should take it, when, and what else they are already taking. Eligibility has generally focused on people at higher risk of severe illness, though the specifics have shifted as the pandemic has evolved and population immunity has grown.
How Paxlovid Stops the Virus
Paxlovid is actually two drugs packaged together. The active antiviral component, nirmatrelvir, targets a specific viral enzyme called the main protease (also known as the 3CL protease). SARS-CoV-2 relies on this enzyme to chop up the large protein chains it produces after entering a human cell. Without that chopping step, the virus cannot assemble the molecular machinery it needs to make copies of itself. Nirmatrelvir binds to the protease’s active site and blocks it, effectively halting viral replication at an early stage.1PubMed Central. Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
The second component, ritonavir, is not there to fight the virus directly. Nirmatrelvir on its own gets broken down too quickly by a liver enzyme called CYP3A4. Ritonavir blocks that enzyme, which slows the breakdown of nirmatrelvir and keeps it circulating in the blood long enough to do its job. With ritonavir on board, nirmatrelvir’s main route of elimination shifts to the kidneys instead of the liver.2PubMed Central. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir This pharmacological trick is borrowed from HIV medicine, where ritonavir has been used for decades as a booster for other antiviral drugs.
How Remdesivir and Molnupiravir Work
While Paxlovid targets a viral protease, remdesivir and molnupiravir both go after the virus’s copying machinery, the RNA-dependent RNA polymerase (RdRp). They just do it in different ways.
Remdesivir is given by intravenous infusion. Once inside a cell, it gets converted into a molecule that mimics one of the building blocks of RNA. The viral polymerase incorporates this imposter into the growing RNA strand. A few bases later, the strand gets stuck. Structural studies have shown that part of the remdesivir molecule physically clashes with a component of the polymerase, preventing the strand from moving forward and stalling replication.3PubMed Central. Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication The polymerase essentially jams after incorporating remdesivir, and the partially built RNA strand goes nowhere.4PubMed Central. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Molnupiravir takes a more chaotic approach. Its active form, called NHC, also gets incorporated into new viral RNA by the polymerase. But instead of stalling the chain, NHC is chemically ambiguous: it can pair with two different RNA bases depending on its shape at any given moment. When the virus later tries to use the NHC-containing RNA as a template, the polymerase reads the NHC as either of two bases and inserts the wrong building block roughly half the time.5PubMed Central. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis The result is a flood of errors scattered across the viral genome. Most of these mutations are harmful or lethal to the virus, so the overall viral population collapses. This strategy, sometimes called “lethal mutagenesis” or “error catastrophe,” is effective but has raised concerns about what happens when the virus is not fully eliminated, a topic covered later in this article.
The Pivotal Trial That Defined Paxlovid’s Use
The clinical evidence that cemented Paxlovid’s role came from its large randomized trial in unvaccinated, high-risk adults. Among patients who started treatment within three days of symptoms, roughly 0.8% of those receiving nirmatrelvir were hospitalized, compared with about 7% of those on placebo. That translated to a relative risk reduction of roughly 89%. All 13 deaths in the trial occurred in the placebo group.6Massachusetts Medical Society. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 These numbers came from an era before widespread vaccination and before Omicron, so the absolute benefit in today’s population is smaller. But the direction of benefit has held up in real-world studies, particularly for older adults and people with multiple health conditions.
A large retrospective study in South Korea during the Omicron BA.5 wave found that nirmatrelvir/ritonavir cut the odds of severe illness or death by about half for treated patients overall. The benefit was even more pronounced among unvaccinated patients, where the odds of death dropped by roughly 60%.7PubMed Central. Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea A separate Korean analysis found that Paxlovid treatment in patients 60 and older reduced the risk of severe illness or death by about 46%, regardless of vaccination status.8Journal of Korean Medical Science. Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea
Why Timing Is Critical
COVID antivirals are not rescue medications. They work by slowing or stopping viral replication, so they need to be taken while the virus is still actively multiplying, which means the first few days of illness. Paxlovid’s authorization specifies starting treatment within five days of symptoms, but the evidence suggests sooner is better.
A large target-trial emulation using data from over 87,000 Paxlovid users in Hong Kong found that starting treatment within one day of symptoms or diagnosis significantly lowered the risk of hospitalization and death compared to starting on day two or later. Each additional day of delay eroded the benefit further: starting within two days was better than starting on day three or later, and starting within three days was better than waiting four or more.9PubMed Central. Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation The practical takeaway is straightforward: if you test positive and are eligible, get the prescription filled and start as soon as possible. Waiting a couple of days “to see how it goes” costs you real benefit.
Who Is Eligible
Eligibility for COVID antivirals has generally centered on people at higher risk of progressing to severe disease. In the United States, this has meant adults and adolescents (12 and older, weighing at least 40 kg for Paxlovid) who test positive for SARS-CoV-2 and have at least one risk factor for severe outcomes. Risk factors include older age (especially 65 and above), obesity, diabetes, chronic lung disease, heart disease, immunocompromising conditions, and chronic kidney disease, among others.
Remdesivir has a somewhat different patient profile because it requires intravenous infusion over three consecutive days, making it less convenient than an oral pill. It has been used for high-risk outpatients when Paxlovid is contraindicated or unavailable, as well as for hospitalized patients.
Molnupiravir was authorized for adults at high risk when other options were not feasible, though its use has been more controversial and more limited. Its demonstrated benefit in trials was more modest than Paxlovid’s, and the mutagenesis concerns discussed below have further complicated its standing.
The Drug Interaction Problem
The ritonavir in Paxlovid is both the drug’s greatest strength and its biggest practical headache. By blocking CYP3A4, ritonavir does not just keep nirmatrelvir levels up; it also slows the breakdown of many other medications that rely on the same liver enzyme. Roughly 60% of available medications are metabolized at least partly through CYP3A4, making the potential for interactions enormous.10PubMed Central. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences
Some of these interactions are dangerous enough to be absolute contraindications. Case reports and pharmacokinetic studies have documented toxicity risks with blood thinners like rivaroxaban, heart-rhythm drugs like amiodarone, blood-pressure medications in the calcium channel blocker family, statins like atorvastatin, the immunosuppressant tacrolimus, and certain psychiatric medications including clozapine and quetiapine.11PubMed. Pharmacokinetic Interactions of Paxlovid Involving CYP3A Enzymes and P-gp Transporter The concern is not theoretical: ritonavir can sharply raise blood levels of these drugs, pushing them into toxic range during the five-day treatment course.12PubMed Central. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
For people on complicated medication regimens, particularly older adults who take multiple prescriptions, this is often the reason Paxlovid gets bypassed in favor of remdesivir or molnupiravir. Prescribers have to review the full medication list carefully, and in some cases certain drugs can be briefly paused or dose-adjusted for the five-day treatment window. But that requires coordination, and in fast-moving outpatient settings it can be a barrier.
Paxlovid Rebound
Early in Paxlovid’s rollout, reports emerged of patients whose symptoms and viral loads bounced back a few days after finishing the five-day course. This phenomenon, sometimes called “Paxlovid rebound,” attracted intense public attention. Prospective data found viral rebound in about 14% of Paxlovid-treated patients, compared with about 9% in untreated controls. Symptom rebound was also somewhat higher in the Paxlovid group, at about 19% versus 7%.13medRxiv. The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Untreated COVID-19 Participants
Modeling work suggests the rebound likely happens because treatment near the time of symptom onset halts viral replication before the immune system has fully geared up. Once the drug is cleared, the virus can resume copying from a small residual pool. Whether rebound occurs appears sensitive to the timing of treatment initiation and individual differences in immune response.14PubMed Central. An explanation for SARS-CoV-2 rebound after Paxlovid treatment The Hong Kong timing study noted that very early treatment (day zero or one) was associated with a slightly elevated risk of viral rebound compared to later initiation, though the estimates were uncertain due to small sample sizes.9PubMed Central. Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation The clinical consensus has been that the rebound is typically mild and self-limited, and the benefits of early treatment in preventing hospitalization and death outweigh the inconvenience of a brief symptom recurrence.
Elderly Patients, Children, and Pregnancy
Older adults are the population most likely to benefit from Paxlovid, and the available safety data in this group are reassuring. A study of elderly COVID patients with a median age of 82, most of whom had at least one other health condition, found that Paxlovid shortened both hospital stays and the time to viral clearance compared to untreated controls. No serious adverse events were observed.15SpringerLink / Infect Dis Ther. Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients The main challenge in this age group, as noted above, is managing drug interactions with their often extensive medication lists.
Data in children are much thinner. A small cohort study in children aged 6 to 14 found that Paxlovid was tolerated, with only mild side effects in two patients (one case of transient diarrhea, one of temporarily elevated liver enzymes). However, viral shedding times were not notably different from untreated age-matched controls in this small sample.16PubMed Central. The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6–14 years Because severe COVID in children is uncommon, the risk-benefit calculation is different from adults, and routine antiviral treatment is generally reserved for children with significant underlying conditions.
For pregnant women, evidence is limited but growing. A study during the Omicron wave concluded that Paxlovid appeared effective and safe during pregnancy.17PubMed. Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic Pregnancy is considered a risk factor for severe COVID, so the potential benefit of treatment is real. Still, the data come from observational studies rather than large randomized trials, and the decision typically involves weighing individual risk factors with a clinician.
Resistance on the Horizon
Like all antiviral drugs, Paxlovid faces the ongoing threat of viral resistance. Researchers have identified specific mutations in the main protease gene that reduce nirmatrelvir’s ability to block the enzyme. Key mutations include changes at positions like E166V and several others scattered across the protease’s structure.18Molecular Therapy Nucleic Acids. Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron
Laboratory studies have shown that the E166V mutation, which emerged in viruses passaged repeatedly with nirmatrelvir, confers resistance to the drug. Structural analysis revealed that this mutation disrupts the way two copies of the protease normally link together, a process essential for the enzyme to function. The virus tolerates that disruption enough to survive but becomes less susceptible to nirmatrelvir’s inhibition.19PubMed Central. Structural and virologic mechanism of the emergence of resistance to Mpro inhibitors in SARS-CoV-2 So far, widespread clinical resistance has not been documented in circulating variants, but the concern is real enough that researchers are actively developing next-generation protease inhibitors designed to remain effective against resistant mutations.
One such approach involves non-covalent inhibitors. Nirmatrelvir works by forming a chemical bond directly with the protease’s active site (a covalent mechanism). A drug called ensitrelvir, already approved in Japan, inhibits the same protease without forming that bond, instead relying on hydrogen bonding and other non-covalent interactions.20Communications Biology. Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants In laboratory tests, ensitrelvir showed potency comparable to nirmatrelvir against the wild-type protease. Having drugs with different binding mechanisms could help combat resistance if mutations make one class of inhibitor less effective.
The Molnupiravir Mutagenesis Controversy
Molnupiravir’s mechanism of flooding the viral genome with errors works well in principle, but it raised an uncomfortable question: what if some of those mutated viruses survive and spread? A 2023 analysis published in Nature found strong evidence that exactly this has happened. Researchers identified a distinctive pattern of mutations in SARS-CoV-2 genome databases, characterized by a high proportion of specific base-change types, that appeared almost exclusively after molnupiravir became widely available. The signature was concentrated in countries and age groups where molnupiravir use was highest, and in some cases the mutated viruses had been transmitted onward to other people.21PubMed Central. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
This does not mean molnupiravir created dangerous new variants. Most drug-induced mutations are harmful to the virus, and there is no evidence that molnupiravir-derived lineages have been more transmissible or virulent. But the finding that a treatment drug was contributing novel mutations into the circulating virus pool was enough to generate real concern among virologists and public health officials. It is one reason molnupiravir has generally been positioned as a second-line option behind Paxlovid in most treatment guidelines.
Could Antivirals Prevent Long COVID?
One of the more interesting lines of evidence concerns whether early antiviral treatment might reduce the risk of long COVID, the constellation of lingering symptoms that can follow even a mild acute infection. A large observational study using U.S. Veterans Affairs data found that nirmatrelvir treatment during the acute phase was associated with about a 26% lower risk of developing post-acute sequelae, with reduced risk across a range of specific outcomes including heart rhythm problems, blood clots, fatigue, kidney disease, muscle pain, and cognitive impairment.22medRxiv. Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19
More recently, a randomized controlled trial from Norway (PANORAMIC Norway) provided stronger evidence. Among participants who completed follow-up, roughly 26% of those who received nirmatrelvir/ritonavir met criteria for long COVID at three months, compared to about 43% in the placebo group, a statistically significant 40% relative risk reduction.23The Lancet Infectious Diseases. Efficacy of nirmatrelvir–ritonavir in preventing long COVID (PANORAMIC Norway) This trial was small, so the estimates carry some uncertainty, but it is notable as one of the first randomized trials to show a protective effect against long COVID specifically. If these findings hold up in larger studies, it would significantly strengthen the case for broader antiviral use even in people who might otherwise ride out a mild acute infection.
Access, Cost, and Getting Treatment Quickly
Even the best antiviral is useless if patients cannot get it in time. A nationwide U.S. home-based test-to-treat program found that about 60% of enrollees received oral antivirals within one day of symptom onset, and over 90% within five days. Encouragingly, the speed of prescribing did not differ meaningfully by age, race, insurance status, or prior difficulty accessing care.24PubMed Central. Primary Findings of Nationwide Home-based Test to Treat Program for COVID-19 and Influenza Programs like this, which connect a positive home test result directly to a telehealth consultation and pharmacy delivery, represent the kind of streamlining that the narrow treatment window demands.
Globally, the picture is much more uneven. A licensing agreement has enabled 95 low- and middle-income countries to access affordable generic versions of Paxlovid. But about 39% of global COVID diagnoses occur in middle-income countries excluded from that deal, leaving them to pay higher prices. Compounding the problem, many lower-income settings have limited diagnostic capacity, making it hard to confirm a positive test quickly enough to start treatment within the window that matters.25PubMed Central. Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19 A test-and-treat program across four African countries found that about half of participants were determined eligible and roughly two-thirds were prescribed the drug, with nearly all of those who received it completing the five-day course.26PubMed. Evaluating the introduction of COVID-19 oral antivirals through a test and treat program The adherence numbers are encouraging, but the eligibility bottleneck shows how much diagnostic and clinical infrastructure still matters.
On cost-effectiveness, modeling studies have reached broadly favorable conclusions for high-risk patients. A Portuguese analysis found Paxlovid to be cost-effective at roughly €3,400 per quality-adjusted life year gained compared to standard care, well below typical willingness-to-pay thresholds.27Value in Health. Cost-Effectiveness of Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in Portugal A U.S. modeling study showed more sensitivity to drug price and to how much benefit a given patient stood to gain, with cost-effectiveness varying considerably depending on assumptions about both.28PubMed Central. Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk As the pandemic has shifted and baseline hospitalization rates have dropped, the per-patient benefit shrinks, which makes the price tag matter more.
“Paxlovid Mouth” and Finishing the Course
Ask anyone who has taken Paxlovid about their experience and the first thing they often mention is the taste. A persistent bitter or metallic flavor, colloquially known as “Paxlovid mouth,” is one of the most common side effects. Research has identified nirmatrelvir as the culprit, showing that it activates a specific bitter taste receptor on the tongue.29PubMed. Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir In an outpatient study, over 60% of patients reported altered taste, making it the single most frequent complaint. Other common side effects included diarrhea and dizziness, though these generally appeared within a couple of hours of dosing and resolved within a day of finishing the course.30Research in Clinical Pharmacy. Mixed-Methods Study of Nirmatrelvir/Ritonavir Treatment for Mild COVID-19 in an Outpatient Setting in China
The taste issue is not just an annoyance; it affects whether people finish the full five-day course. In that same study, the three most common reasons patients considered stopping early were feeling better before the course was done, not fully understanding why five days mattered, and the side effects themselves. One patient wanted to quit on day three but was talked back into finishing by a pharmacist who suggested taking green tea and ice before each dose to mask the bitterness. Simple workarounds like these, combined with clear communication at the pharmacy counter about why completing the full course matters, can make a real difference in adherence. The concern with stopping early is not just reduced efficacy for the individual patient but also the potential for incomplete viral suppression to contribute to resistance over time.